In his interview with Brent Cook, Jim Puplava sounds amazed that so few juniors are being acquired while they are now so cheap. Brent explains that many apparently attractive cheap juniors have not so obvious fatal flaws, warts, that devalues them as potential buyouts. But, on the other end of the spectrum, according to Cook, there are excellent companies with large economic deposits, but they´re overpriced.

My point.

Once the Feasibility Study is delivered, I´d like to see it scoured by independent analysts, not by any self-professed experts on Tyhee chat rooms. Let´s get more professional support for the essential value for this company, warts and all.